Navigation Links
ASTRO publishes whole breast irradiation guidelines
Date:8/4/2010

The American Society for Radiation Oncology (ASTRO) has released evidence-based guidelines to define appropriate fractionation of whole breast irradiation (WBI), finding that hypofractionated (HF) WBI is effective for many patients with early-stage breast cancer. These guidelines are published in the International Journal of Radiation OncologyBiologyPhysics, the official journal of ASTRO.

Studies have shown that WBI following breast conserving surgery lowers the risk of tumor recurrence and improves survival. Most studies used conventionally fractionated (CF) radiation, which involves daily treatments for up to seven weeks. Despite its effectiveness, conventional fractionation has some drawbacks, including the inconvenience associated with undergoing treatment for a long period of time and the total costs, including both direct health care expenditures and opportunity costs to the patient from being away from home and work.

HF-WBI is a type of WBI that uses a higher dose for each treatment but fewer total treatments, so patients can typically finish radiation in four weeks or less. Several trials have found little difference in the local control and survival outcomes for selected patients treated with either CF-WBI or HF-WBI.

The ASTRO Health Services Research Committee convened a task force and answered the questions:

  1. Which patients obtain equivalent results from HF-WBI and CF-WBI?
  2. What is the role of a tumor-bed radiation boost in patients treated with HF-WBI?
  3. What are appropriate regiments for HF-WBI and tumor-bed boost?
  4. What are the characteristics of an acceptable radiotherapy plan for patients treated with HF-WBI?
  5. What insights relevant to the radiobiology of breast cancer can be gained from recently published clinical trials comparing CF-WBI with HF-WBI?

The task force concluded that HF-WBI is just as effective as CF-WBI for early-stage breast cancer patients who meet specific criteria. These criteria include age 50 years and older, stage T1-2 N0, not receiving chemotherapy, relatively uniform delivery of the radiation dose and the ability to exclude the heart from the path of the radiation beam. For patients who do not meet these criteria, there was not enough evidence to reach a consensus for or against the use of HF-WBI.

"Widespread adoption of HF-WBI for appropriately selected patients has the potential to enhance the convenience of treatment and lower the costs of WBI," Benjamin D. Smith, M.D., lead author of the study and a radiation oncologist at the University of Texas M.D. Anderson Cancer Center in Houston, said. "For patients where the data to support HF-WBI are not as strong, HF-WBI can still be considered an option but further research is needed."


'/>"/>

Contact: Beth Bukata
bethb@astro.org
703-839-7332
American Society for Radiation Oncology
Source:Eurekalert

Related medicine news :

1. ASTRO names radiologist, ABR president Societys 2010 Honorary Member
2. 5 awarded ASTRO research grants
3. ASTRO announces 2010 Fellows class
4. Optimal surgical procedure for duodenal gastrointestinal stromal tumors
5. What affects the gastrointestinal symptoms in peritoneal dialysis patients?
6. ASTRO applauds MedPAC review of Stark law exception
7. ASTRO participates in FDA meeting on radiation safety
8. Florida radiation council endorses ASTRO patient protection plan
9. ASTRO patient education program recognized by AAA Awards
10. Gulf Oil Spill Goes from Disaster to Catastrophe
11. Larson, McBride named 2010 ASTRO Gold Medalists
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... ... February 24, 2017 , ... With millions of Americans and ... that we all are aware of our options and are empowered with strength ... the launch of its newest edition of "Vision and Hearing" in USA Today, ...
(Date:2/24/2017)... Texas (PRWEB) , ... February 24, 2017 , ... Yisrayl ... that focuses on Bible Prophecy concerning this present generation. Yisrayl makes an astounding ... this current generation. He explains that the Bible details the current times so ...
(Date:2/24/2017)... Emeryville, CA (PRWEB) , ... February 24, 2017 ... ... Esparza for qualifying into the Senior International Elite division on February 12th. ... All Around divisions at the elite qualifier competition held in Las Vegas, Nevada. ...
(Date:2/23/2017)... ... February 23, 2017 , ... ... exclusively to funding innovative lymphoma research and serving the lymphoma community through a ... to the La Gorce Country Club in Miami Beach to host its Swirl: ...
(Date:2/23/2017)... ... 23, 2017 , ... Rosica Communications, a national PR ... media management, corporate communications, SEO and cause marketing, is opening an office in ... Hampshire, Massachusetts and Canada, Rosica will focus on expanding its footprint. , ...
Breaking Medicine News(10 mins):
(Date:2/24/2017)...  In conjunction with DURECT Corporation,s (Nasdaq: ... you are invited to listen to a conference call ... Tuesday, March 14, 2017 at 4:30 pm Eastern Time ... webcast of the presentation will be available by accessing ... Relations."  If you are unable to participate during the ...
(Date:2/24/2017)... Report analyzes the worldwide markets for Endodontic Supplies in US$ ... Canada , Japan , ... Latin America , and Rest of World. ... through 2022. Also, a six-year historic analysis is provided for ... and secondary research. Company profiles are primarily based on public ...
(Date:2/24/2017)... 23, 2017  This report analyzes the worldwide markets ... Products: Intermediates, Analytical, and Others. The ... Pharmaceuticals, and Agrochemicals. The report provides separate comprehensive analytics ... Europe , and Rest of World. Annual ... through 2022. Also, a six-year historic analysis is provided ...
Breaking Medicine Technology: